Inactivated influenza H7N9 vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Avian InfluenzaInfluenzaInfluenza Immunisation

Phase 2

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

CompletedNCT03312231

National Institute of Allergy and Infectious Diseases (NIAID)Avian Influenza, Influenza Immunisation

Start: 2018-02-14End: 2019-09-26Updated: 2024-09-19

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

CompletedNCT03318315

National Institute of Allergy and Infectious Diseases (NIAID)Avian Influenza, Influenza, Influenza Immunisation

Start: 2018-02-20End: 2019-07-25Updated: 2020-08-06

Related Papers

Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens.

2025-01-042 citations

Immunogenicity and Safety of AS03‐Adjuvanted H7N9 Influenza Vaccine in Adults (18–64 and ≥65 Years): A Phase 1/2, Randomized, Placebo‐Controlled Trial

Influenza and Other Respiratory Viruses2024-12-01

Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial.

2022-04-227 citations

A Phase 1 Randomized Placebo-Controlled Study to Assess the Safety, Immunogenicity and Genetic Stability of a New Potential Pandemic H7N9 Live Attenuated Influenza Vaccine in Healthy Adults

Vaccines2020-06-107 citations